Diagnosis and Treatment of Depression Comorbid with Neurologic Disorders

American Journal of Medicine

Volumn 121, Issue 11 SUPPL. 2, 2008, Pages

  Raskind, Murray A ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer disease; Antidepressants; Depression; Multiple sclerosis; Parkinson disease; Stroke

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; REBOXETINE; SERTRALINE; TRAZODONE;

AGITATION; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DELIRIUM; DEPRESSION; DISABILITY; DROWSINESS; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SIDE EFFECT; STROKE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSION; HUMANS; NERVOUS SYSTEM DISEASES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY;

EID: 54049094447     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.08.007     Document Type: Article

References (107)

1. Evans D.L., Charney D.S., Lewis L., et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58 (2005) 175-189
2. Katon W., and Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res. 53 (2002) 859-863
3. Lee H.B., and Lyketsos C.G. Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry 54 (2003) 353-362
4. Rickards H. Depression in neurological disorders: an update. Curr Opin Psychiatry 19 (2006) 294-298
5. Gallo J.J., and Rabins P.V. Depression without sadness: alternative presentations of depression in late life. Am Fam Physician 60 (1999) 820-826
6. Lyketsos C.G., and Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 52 (2002) 243-252
7. Stover E., Fenton W., Rosenfeld A., and Insel T.R. Depression and comorbid medical illness: the National Institute of Mental Health perspective. Biol Psychiatry 54 (2003) 184-186
8. Burns A., Jacoby R., and Levy R. Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood. Br J Psychiatry 157 (1990) 81-86 92-94
9. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., and Breitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157 (2000) 708-714
10. Harwood D.G., Barker W.W., Ownby R.L., and Duara R. Association between premorbid history of depression and current depression in Alzheimer's disease. J Geriatr Psychiatry Neurol 12 (1999) 72-75
11. Gonzalez-Salvador M.T., Arango C., Lyketsos C.G., and Barba A.C. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 14 (1999) 701-710
12. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord. 11 suppl 4 (1997) S35-S38
13. Logsdon R.G., McCurry S.M., Moore A.L., and Teri L. Family and caregiver issues in the treatment of patients with Alzheimer's disease. Semin Clin Neuropsychiatry 2 (1997) 138-151
14. Gonzalez-Salvador T., Lyketsos C.G., Baker A., et al. Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry 15 (2000) 181-189
15. Lyketsos C.G., Steele C., Baker L., et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci. 9 (1997) 556-561
16. Lyketsos C.G., Steele C., Galik E., et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 156 (1999) 66-71
17. Steele C., Rovner B., Chase G.A., and Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147 (1990) 1049-1051
18. Kopetz S., Steele C.D., Brandt J., et al. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15 (2000) 586-593
19. Bassuk S.S., Berkman L.F., and Wypij D. Depressive symptomatology and incident cognitive decline in an elderly community sample. Arch Gen Psychiatry 55 (1998) 1073-1081
20. Rovner B.W., German P.S., Brant L.J., Clark R., Burton L., and Folstein M.F. Depression and mortality in nursing homes. JAMA 265 (1991) 993-996
21. Reifler B.V., Teri L., Raskind M., et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 146 (1989) 45-49
22. Petracca G., Teson A., Chemerinski E., Leiguarda R., and Starkstein S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 8 (1996) 270-275
23. Nyth A.L., Gottfries C.G., Lyby K., et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 86 (1992) 138-145
24. Magai C., Kennedy G., Cohen C.I., and Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 8 (2000) 66-74
25. Lyketsos C.G., Sheppard J.M., Steele C.D., et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 157 (2000) 1686-1689
26. Robinson R.G. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 54 (2003) 376-387
27. Carota A., and Bogousslavsky J. Poststroke depression. Adv Neurol. 92 (2003) 435-445
28. Paradiso S., and Robinson R.G. Gender differences in poststroke depression. J Neuropsychiatry Clin Neurosci. 10 (1998) 41-47
29. Robinson R.G., Kubos K.L., Starr L.B., Rao K., and Price T.R. Mood disorders in stroke patients: importance of location of lesion. (pt 1). Brain 107 (1984) 81-93
30. Carson A.J., MacHale S., Allen K., et al. Depression after stroke and lesion location: a systematic review. Lancet 356 (2000) 122-126
31. Bhogal S.K., Teasell R., Foley N., and Speechley M. Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke 35 (2004) 794-802
32. de Coster L., Leentjens A.F., Lodder J., and Verhey F.R. The sensitivity of somatic symptoms in post-stroke depression: a discriminant analytic approach. Int J Geriatr Psychiatry 20 (2005) 358-362
33. Spalletta G., Ripa A., and Caltagirone C. Symptom profile of DSM-IV major and minor depressive disorders in first-ever stroke patients. Am J Geriatr Psychiatry 13 (2005) 108-115
34. Carota A., Berney A., Aybek S., et al. A prospective study of predictors of poststroke depression. Neurology 64 (2005) 428-433
35. Feibel J.H., and Springer C.J. Depression and failure to resume social activities after stroke. Arch Phys Med Rehabil. 63 (1982) 276-277
36. Gainotti G., Antonucci G., Marra C., and Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 71 (2001) 258-261
37. House A., Dennis M., Warlow C., Hawton K., and Molyneux A. The relationship between intellectual impairment and mood disorder in the first year after stroke. Psychol Med. 20 (1990) 805-814
38. Kauhanen M., Korpelainen J.T., Hiltunen P., et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 30 (1999) 1875-1880
39. Lenze E.J., Rogers J.C., Martire L.M., et al. The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research. Am J Geriatr Psychiatry 9 (2001) 113-135
40. Larson S.L., Owens P.L., Ford D., and Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore Epidemiologic Catchment Area Study. Stroke 32 (2001) 1979-1983
41. May M., McCarron P., Stansfeld S., et al. Does psychological distress predict the risk of ischemic stroke and transient ischemic attack?. The Caerphilly Study. Stroke 33 (2002) 7-12
42. Lipsey J.R., Robinson R.G., Pearlson G.D., Rao K., and Price T.R. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1 (1984) 297-300
43. Reding M.J., Orto L.A., Winter S.W., Fortuna I.M., Di Ponte P., and McDowell F.H. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol. 43 (1986) 763-765
44. Andersen G., Vestergaard K., and Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25 (1994) 1099-1104
45. Wiart L., Petit H., Joseph P.A., Mazaux J.M., and Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31 (2000) 1829-1832
46. Robinson R.G., Schultz S.K., Castillo C., et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157 (2000) 351-359
47. Chen Y., Patel N.C., Guo J.J., and Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 22 (2007) 159-166
48. Robinson R.G., Jorge R.E., Moser D.J., et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299 (2008) 2391-2400
49. Allain H., Schuck S., and Mauduit N. Depression in Parkinson's disease. BMJ 320 (2000) 1287-1288
50. Ranoux D. Depression and Parkinson disease. [in French]. Encephale. 26 (2000) 22-26
51. McDonald W.M., Richard I.H., and DeLong M.R. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54 (2003) 363-375
52. Ehrt U., Bronnick K., Leentjens A.F., Larsen J.P., and Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry 21 (2006) 252-258
53. Leentjens A.F., Verhey F.R., Lousberg R., Spitsbergen H., and Wilmink F.W. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 15 (2000) 644-649
54. Leentjens A.F., Verhey F.R., Luijckx G.J., and Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 15 6 (2000) 1221-1224
55. Levin B.E., Llabre M.M., and Weiner W.J. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 51 (1988) 1401-1404
56. Edwards E., Kitt C., Oliver E., Finkelstein J., Wagster M., and McDonald W.M. Depression and Parkinson's disease: a new look at an old problem. Depress Anxiety 16 (2002) 39-48
57. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry 149 (1992) 443-454
58. Starkstein S.E., Petracca G., Chemerinski E., et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord. 13 (1998) 29-33
59. Starkstein S.E., Preziosi T.J., Bolduc P.L., and Robinson R.G. Depression in Parkinson's disease. J Nerv Ment Dis. 178 (1990) 27-31
60. Arabia G., Grossardt B.R., Geda Y.E., et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry 64 (2007) 1385-1392
61. Papapetropoulos S., Ellul J., Argyriou A.A., Chroni E., and Lekka N.P. The effect of depression on motor function and disease severity of Parkinson's disease. Clin Neurol Neurosurg. 108 (2006) 465-469
62. Kuhn W., Heye N., Muller T., et al. The motor performance test series in Parkinson's disease is influenced by depression. J Neural Transm. 103 (1996) 349-354
63. Kuzis G., Sabe L., Tiberti C., Leiguarda R., and Starkstein S.E. Cognitive functions in major depression and Parkinson disease. Arch Neurol. 54 (1997) 982-986
64. Starkstein S.E., Bolduc P.L., Mayberg H.S., Preziosi T.J., and Robinson R.G. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry 53 (1990) 597-602
65. Stefanova E., Potrebic A., Ziropadja L., Maric J., Ribaric I., and Kostic V.S. Depression predicts the pattern of cognitive impairment in early Parkinson's disease. J Neurol Sci. 248 (2006) 131-137
66. Findlay L.J., and Global Parkinson's Disease Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 17 (2002) 60-67
67. Andersen J., Aabro E., Gulmann N., Hjelmsted A., and Pedersen H.E. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand. 62 (1980) 210-219
68. Wermuth L., Sørensen P.S., Timm S., et al. Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry 52 (1998) 163-169
69. Antonini A., Tesei S., Zecchinelli A., et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 21 (2006) 1119-1122
70. Lemke M.R. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 63 (2002) 300-304
71. Lemke M.R., Brecht H.M., Koester J., and Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci. 248 (2006) 266-270
72. Barone P., Scarzella L., Marconi R., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 253 (2006) 601-607
73. Chwastiak L., Ehde D.M., Gibbons L.E., Sullivan M., Bowen J.D., and Kraft G.H. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 159 (2002) 1862-1868
74. Gottberg K., Einarsson U., Fredrikson S., von Koch L., and Widen Holmqvist L. A population-based study of depressive symptoms in multiple sclerosis in Stockholm County: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry 78 (2007) 60-65
75. Patten S.B., Metz L.M., and Reimer M.A. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 6 (2000) 115-120
76. McIvor G.P., Riklan M., and Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support. J Clin Psychol. 40 (1984) 1028-1033
77. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry 115 (1969) 749-764
78. Rabins P.V., Brooks B.R., O'Donnell P., et al. Structural brain correlates of emotional disorder in multiple sclerosis. Brain 109 pt 4 (1986) 585-597
79. Moller A., Wiedemann G., Rohde U., Backmund H., and Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand. 89 (1994) 117-121
80. McGuigan C., and Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 253 (2006) 219-223
81. Gold S.M., and Irwin M.R. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin. 24 (2006) 507-519
82. Mohr D.C., and Goodkin D.E. Treatment of depression in multiple sclerosis: review and meta-analysis. Clinical Psychology: Science and Practice 18 (1999) 1-9
83. Caine E.D., and Schwid S.R. Multiple sclerosis, depression, and the risk of suicide. Neurology 59 (2002) 662-663
84. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 59 (2002) 674-678
85. Gilchrist A.C., and Creed F.H. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res. 38 (1994) 193-201
86. Krupp L.B., Sliwinski M., Masur D.M., Friedberg F., and Coyle P.K. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 51 (1994) 705-710
87. Schiffer R.B., and Caine E.D. The interaction between depressive affective disorder and neuropsychological test performance in multiple sclerosis patients. J Neuropsychiatry Clin Neurosci. 3 (1991) 28-32
88. Arnett P.A., Higginson C.I., Voss W.D., et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 13 (1999) 434-446
89. Maor Y., Olmer L., and Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients-the role of depression. Mult Scler. 7 (2001) 131-135
90. Smith S.J., and Young C.A. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil. 14 (2000) 50-54
91. Benedict R.H., Wahlig E., Bakshi R., et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 231 (2005) 29-34
92. Mohr D.C., Goodkin D.E., Likosky W., Gatto N., Baumann K.A., and Rudick R.A. Treatment of depression improves adherence to interferon β-1b therapy for multiple sclerosis. Arch Neurol. 54 (1997) 531-533
93. H1 responses in multiple sclerosis. Arch Neurol. 58 (2001) 1081-1086
94. Schiffer R.B., and Wineman N.M. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 147 (1990) 1493-1497
95. Ehde D.M., Kraft G.H., Chwastiak L., et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 30 (2008) 40-48
96. Mohr D.C., Hart S., and Vella L. Reduction in disability in a randomized controlled trial of telephone-administered cognitive-behavioral therapy. Health Psychol. 26 (2007) 554-563
97. Hart S., Fonareva I., Merluzzi N., and Mohr D.C. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res. 14 (2005) 695-703
98. Mohr D.C., Boudewyn A.C., Goodkin D.E., Bostrom A., and Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 69 (2001) 942-949
99. Mohr D.C., Hart S.L., and Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med. 65 (2003) 542-547
100. Mohr D.C., Hart S.L., Fonareva I., and Tasch E.S. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 12 (2006) 204-208
101. Mohr D.C., Hart S.L., Julian L., and Tasch E.S. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler. 13 (2007) 215-219
102. Dell'Agnello G., Ceravolo R., Nuti A., et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 24 (2001) 221-227
103. Laitinen L. Desipramine in treatment of Parkinson's disease: a placebo-controlled study. Acta Neurol Scand. 45 (1969) 109-113
104. Thompson S., Herrmann N., Rapoport M.J., and Lanctot K.L. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 52 (2007) 248-255
105. Wellbutrin XL. [package insert] (2007), GlaxoSmithKline, Research Triangle Park, NC
106. Hunkeler E.M., Meresman J.F., Hargreaves W.A., et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med. 9 (2000) 700-708
107. Simon G.E., VonKorff M., Rutter C., and Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ 320 (2000) 550-554